Local Recurrence After Surgery for Early Stage Lung Cancer
|
|
- Amice Kathryn Owens
- 5 years ago
- Views:
Transcription
1 Original Article Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients Chris R. Kelsey, MD 1 ; Lawrence B. Marks, MD 2 ; Donna Hollis, MS 3 ; Jessica L. Hubbs, MS 2 ; Neal E. Ready, MD, PhD 4 ; Thomas A. D Amico, MD 5 ; and Jessamy A. Boyd, MD 1 BACKGROUND: The objective of the current study was to evaluate the actuarial risk of local failure (LF) after surgery for stage I to II nonsmall cell lung cancer (NSCLC) and assess surgical and pathologic factors affecting this risk. METHODS: The records, including pertinent radiologic studies, of all patients who underwent surgery for T1 to T2, N0 to N1 NSCLC at Duke University between 1995 and 2005 were reviewed. Risks of disease recurrence were estimated using the Kaplan-Meier method. A multivariate Cox regression analysis assessed factors associated with LF in the entire cohort and a subgroup undergoing optimal surgery for stage IB to II disease. RESULTS: For all 975 consecutive patients, the 5-year actuarial risk of local and/or distant disease recurrence was 36%. First sites of failure were local only (25%), local and distant (29%), and distant only (46%). The 5-year actuarial risk of LF was 23%. On multivariate analysis, squamous/ large cell histology (hazards ratio [HR], 1.98), stage > IA (HR, 2.02), and sublobar resections (HR, 1.99) were found to be independently associated with a higher risk of LF. For the subset of patients (n ¼ 445) undergoing at least a lobectomy with negative surgical margins and currently considered for adjuvant chemotherapy (stage IB-II disease), the 5-year actuarial risk of LF was 27%. Within this subgroup, squamous/large cell histology (HR, 2.5) and lymphovascular space invasion (HR, 1.74) were associated with a higher risk of LF. The 5-year rate of LF was 13%, 32%, and 47%, respectively, with 0, 1, or 2 risk factors. CON- CLUSIONS: Greater than half of disease recurrences after surgery for early stage NSCLC involved local sites. Pathologic factors may help to distinguish those patients at highest risk. Cancer 2009;115: VC 2009 American Cancer Society. KEY WORDS: nonsmall cell lung cancer, local recurrence, local/regional recurrence, patterns of failure, radiotherapy. Surgery is the preferred initial treatment for patients with early stage nonsmall cell lung cancer (NSCLC). Due to the relatively high risk of disease recurrence after surgery, adjuvant radiotherapy (RT) Corresponding author: Chris R. Kelsey, MD, Department of Radiation Oncology, Duke University Medical Center 3085, Durham, NC 27710; Fax: (919) ; kelse003@mc.duke.edu 1 Department of Radiation Oncology, Duke University Medical Center, Durham, rth Carolina; 2 Department of Radiation Oncology, University of rth Carolina, Chapel Hill, rth Carolina; 3 Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, rth Carolina; 4 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, rth Carolina; 5 Department of Surgery, Duke University Medical Center, Durham, rth Carolina Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30-June 3, 2008; and the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, Massachusetts, September 21-25, We thank Thomas A. Sporn, MD, from the Department of Pathology at Duke University for reviewing the text and providing invaluable suggestions. Received: December 1, 2008; Revised: May 14, 2009; Accepted: May 15, 2009 Published online August 11, 2009 in Wiley InterScience ( DOI: /cncr.24625, Cancer vember 15, 2009
2 Local Recurrence of Early Stage Lung Cancer/Kelsey et al and chemotherapy have each been investigated in randomized clinical trials. Several trials demonstrated that postoperative RT reduced the risk of local/regional (ie, local) disease recurrence. 1-3 However, RT was found to have either no effect, 1 or a detrimental effect, 3,4 on survival, due to competing risks of distant metastases and treatment-related mortality. Early adjuvant chemotherapy studies demonstrated a survival detriment with alkylating agents. 5 More recently, cisplatin-based regimens have demonstrated survival benefits in certain subsets of patients with early stage NSCLC. 6-8 An accurate assessment of patterns of failure after surgery is helpful to guide effective postoperative therapy. At the current time, adjuvant treatment is focused on chemotherapy and the risk of distant metastases. Postoperative RT is not currently being pursued out of concern for treatment-related toxicity. Furthermore, the risk of local recurrence is generally considered to be small in comparison with the risk of distant recurrence. However, the risk of local disease recurrence after surgery has not been well described and pathologic features placing patients at particularly high risk of local recurrence have been inadequately studied. This patterns-of-failure analysis was initiated to provide insight into these issues. MATERIALS AND METHODS This Institutional Review Board-approved retrospective study was performed by searching the Duke Comprehensive Cancer Center database for patients who underwent surgery for T1 to T2, N0 to N1 NSCLC at Duke University between 1995 and Patients who received preoperative chemotherapy and/or RT, presented with synchronous primary tumors, or had a prior history of lung cancer were excluded. Medical records and pertinent radiologic imaging were reviewed to characterize each patient s demographic information, obtain surgical and pathologic details, and score patterns of failure after surgery. Between 1995 and 1997, lung tumor specimens were interpreted by multiple pathologists at Duke University. After 1998, all specimens were interpreted by a single pathologist with a special interest in pulmonary pathology (T.A. Sporn). Hematoxylin and eosin stains were performed on all specimens. Elastin stains were used when necessary to evaluate involvement of the visceral pleura. Other pathologic studies, including immunostains, were performed at the discretion of the pathologist. Lymphovascular space invasion was reported when tumor emboli involved lymphatic, venous, and/or arterial channels. The primary objective of the current study was to assess the risk of local disease recurrence after surgery and to identify clinical, surgical, and pathologic features associated with a higher risk of local recurrence. Disease recurrence at the surgical resection margin, ipsilateral hilum, and/or mediastinum was considered a local (ie, local/regional) recurrence. All other sites of failure, including the supraclavicular fossa and contralateral hilum, were considered distant recurrences. Patterns of failure were assessed by means of followup imaging studies and data obtained from procedures such as bronchoscopy, mediastinoscopy, etc. Hilar and mediastinal lymph node failures were defined as a new or enlarging lymph node measuring 1 cm on the short axis on computed tomography (CT), and/or hypermetabolic on positron emission tomography (PET) imaging, which in the patient s subsequent clinical follow-up was consistent with disease progression. Thus, an enlarged lymph node or increased tissue thickening at the resection margin, or equivocal findings on PET, that failed to progress were not scored as a local recurrence. All cases of possible local and distant disease recurrence were reviewed by 2 authors to ensure accuracy (C.K. and J.B.). All patients had routine postsurgical surveillance with imaging studies, including chest CT, but testing was not standardized. Secondary objectives were to assess the risk of distant disease recurrence and the development of second primary lung cancers. A second primary tumor was scored when a patient presented with a different histology or the same histology but a clinical presentation that was most consistent with a new primary tumor. Distinguishing a second primary malignancy from a local and/or distant recurrence required clinical judgment, and such cases were reviewed by 2 authors (C.K. and J.B.). The Kaplan-Meier product-limit method 9,10 was used to estimate 5-year recurrence probabilities and 95% confidence intervals (95% CIs). Time to treatment failure was calculated from the date of surgery to the date of treatment failure (defined as local and/or distant recurrence or the development of a second primary lung cancer). Time to local failure and time to distant failure were calculated from the date of surgery to the date of local or distant Cancer vember 15,
3 Original Article disease recurrence, respectively. For these metrics, patients developing a second primary lung cancer were censored on the date the second primary malignancy was diagnosed, because it was often impractical to distinguish a local failure arising from the first versus the second lung cancer. Local and distant recurrences were scored independently (ie, patients developing a distant recurrence were not censored for local failure, but were assessed for local failure until the date of last follow-up or death). Presented median recurrence times were calculated using only those patients who had recurrent disease. A Fisher exact test was used to calculate all 2 2 table probabilities of independence. 11 Univariate Cox proportional hazards models 9,10 were used to assess the strength of the association between time to disease recurrence and surgical and pathologic risk factors (covariates), and to estimate hazards ratios (HR) and 95% CIs using the Wald chi-square statistic. The assumption of proportional hazards was assessed by adding each covariate by log time interaction to the model and assessing the significance of the product term using the partial likelihood ratio test. Stages and histologies were combined according to similar HRs. In the multivariate Cox proportional hazards regression model, all variables with P values <.10 in the univariate analysis were included and a stepwise variable selection approach was used, with entrance and exit significance levels of.05. Kaplan-Meier survival plots were used to assess subgroup survival similarities. This univariate/multivariate approach was performed on the entire patient cohort, and repeated in a subgroup of patients undergoing optimal surgery (at least lobectomy with negative margins) and currently considered potential candidates for adjuvant chemotherapy (those with stage IB-II disease per the American Joint Committee on Cancer staging system, 6th edition). All statistical tests were 2-sided and a P value <.05 was considered statistically significant. SAS 9.1 statistical software (SAS Institute, Inc, Cary, NC) was used for all statistical analyses. RESULTS We identified 975 patients. The median follow-up was 33 months (range, months). Patient characteristics and surgical/pathologic details are shown in Table 1. The majority of patients had stage I disease (45% with stage IA and 39% with stage IB). Hilar lymph nodes (N1, levels 10-14) were sampled in 81% of patients. The median number of N1 lymph nodes sampled was 4 (range, 1-31 N1 lymph nodes). Mediastinal lymph nodes (N2, levels 1-9) were sampled or dissected in 85% of patients. The median number of mediastinal lymph node stations examined was 4 (range, 1-9 mediastinal lymph node stations). Surgical margins were positive in 4% of patients. Adjuvant chemotherapy was administered to 7% of patients. Carboplatin and paclitaxel were used most frequently (49%), although several regimens were used. Adjuvant RT was given to 3% of patients. Patients with positive surgical margins were more likely to receive adjuvant RT than patients with negative surgical margins (31% vs 2%; P <.0001). Considering all 975 patients, the 5-year actuarial risk of treatment failure (local and/or distant disease recurrence or diagnosis of a second primary lung cancer) was 42% (95% CI, 38-46%) (Fig. 1). A local and/or distant recurrence developed in 250 patients. First sites of failure were local only (25%), local and distant (29%), and distant only (46%). The 5-year actuarial risk of local and/or distant recurrence was 36%. A second primary lung cancer was diagnosed in 45 patients. Local disease recurrence was identified in 140 patients. Diseaserecurrencewasconfirmedbymeansofbiopsyin 47% of patients, PET in 33% of patients, and CT in 20% of patients. Distribution of local failures were as follows: mediastinum (36%), ipsilateral hilum (11%), wedge resection line (10%), bronchial stump (9%), and multiple subsites (34%). The median time from surgery to local recurrence was 14.1 months (range, 1-78 months) for those patients with local recurrence. The 5-year actuarial risk of local disease recurrence was 23% (95% CI, 19-26%) (Fig. 2). Distant recurrence was identified in 207 patients and was pathologically confirmed in 103. The median time from surgery to distant disease recurrence was 12.5 months (range, 1-79 months) for those developing distant metastases. For all patients, the 5-year actuarial rate of distant disease recurrence was 34% (95% CI, 30-39%). The risk of local recurrence was higher for patients withstageib,iia,andiibdiseasecomparedwiththose with stage IA disease (HRs of 2.0, 2.6, and 1.9, respectively; P ¼.0001). Variables associated with a higher rate of local failure on univariate analysis were sublobar resections (HR, 1.64), lack of mediastinal lymph node sampling (HR, 1.65), increasing size (HR, 1.13 per cm), 5220 Cancer vember 15, 2009
4 Local Recurrence of Early Stage Lung Cancer/Kelsey et al Table 1. Patient and Treatment Characteristics (N¼975) Characteristic. % Age, y Mean 66.4 Median 67 Range Gender Male Female Race White Black Other 27 2 Surgical procedure Wedge Segmentectomy 41 4 Lobectomy Sleeve resection 36 4 Pneumonectomy 69 7 Surgical approach Open VATS Hilar lymph node sampling Yes Mediastinal lymph node sampling Yes Size, cm Mean 3.23 Median 2.6 Range Location Right upper lobe Right middle lobe 51 5 Right lower lobe Right lung, NOS 2 <1 Left upper lobe Left lower lobe Histology Adenocarcinoma Squamous cell* Large cell 48 5 Bronchioloalveolar 28 3 NSCLC, NOS Histologic differentiation Well 77 8 Moderate Poor NS Lymphovascular space invasion Yes /NS (Continued) Table 1. (Continued) Characteristic. % Visceral pleural invasion Yes /NS Pathologic stagey IA IB IIA 43 4 IIB Surgical margins Negative Positive 36 4 Adjuvant chemotherapy Yes Adjuvant radiotherapy Yes VATS indicates video-assisted thoracoscopic surgery; NOS, not otherwise specified; NSCLC, nonsmall cell lung cancer; NS, not stated. * Including adenosquamous (n¼6). y Grading determined according to the American Joint Committee on Cancer staging system, 6th edition. FIGURE 1. Kaplan-Meier curve of time to treatment failure (defined as local and/or distant disease recurrence or the development of a second primary lung cancer) is shown. squamous or large cell histology (HR, 2.15), moderate or poorly differentiated grade (HR, 2.88), lymphovascular space invasion (HR, 1.54), visceral pleural invasion (HR, 1.93), stage IB to IIA disease (HR, 2.00), and positive surgical margins (HR, 1.85). A stepwise multivariate proportional hazards analysis resulted in squamous or large cell histology (HR, 1.98), stage > IA (HR, 2.02), and sublobar resection (HR, 1.99) being independently Cancer vember 15,
5 Original Article FIGURE 2. Kaplan-Meier curve of time to local failure is shown. associated with a higher risk of local disease recurrence (Table 2). For the subset of patients (n ¼ 445) undergoing optimal surgery (at least a lobectomy with negative surgical margins) and currently considered for adjuvant chemotherapy (stage IB-II disease), the 5-year actuarial risk of local disease recurrence was 27% (95% CI, 21-33%) and that for distant recurrence was 42% (95% CI, 36-48%). On multivariate analysis within this subgroup of patients, lymphovascular space invasion (HR, 1.74; 95% CI, ) and squamous/large cell histology (HR, 2.5; 95% CI, 1.5-4) were found to be associated with a higher risk of local recurrence (Table 3). The 5-year actuarial risk of local recurrence was 13% (95% CI, 8-22%), 32% (95% CI, 25-41%), and 47% (95% CI, 30-67%), respectively, with 0, 1, or 2 risk factors (Fig. 3). DISCUSSION NSCLC remains the leading cause of cancer mortality in the United States. 12 Even patients with early disease are at relatively high risk of disease recurrence. Cisplatin-based chemotherapy regimens have decreased the risk of recurrence after surgery and provided modest survival gains. An updated meta-analysis from the NSCLC Collaborative Group demonstrated an average survival benefit of 5.4% at 5 years for patients with resected stage I to III disease. 13 Rates of local failure are infrequently reported in adjuvant lung cancer trials. It is generally believed that the risk of local disease recurrence after surgery for patients with early stage NSCLC is low. However, there is substantial variation in the literature, with rates ranging from 6% to 45% for stage I disease 2,3,14-21 and 7% to 55% for stage II disease. 1,18,21-24 There are multiple reasons why the risk of local recurrence is poorly defined. To begin with, the definition of local failure varies widely among publications, even prospective randomized trials. In the Adjuvant Navelbine International Trialist Association (ANITA) trial of chemotherapy versus observation for patients with stage IB to IIIA NSCLC, the crude rate of local failure was 12% in the arm randomized to receive chemotherapy. 7 However, only ipsilateral mediastinal recurrences were scored as local failures. In other words, a contralateral mediastinal recurrence was not considered a local recurrence. We believe the most appropriate definition of local (ie, local/ regional) failure is disease recurrence at the surgical resection margin, ipsilateral hilum, and mediastinum. Practically speaking, these are the sites that are encompassed by typical radiation fields in the postoperative setting. Furthermore, many studies only report first sites of failure. Distant metastases commonly develop after surgery for lung cancer and are typically easier to assess radiologically than local failures. Unless there is a thorough evaluation performed at the time of disease recurrence (to assess for a concurrent local failure), a local recurrence may be missed. It is interesting to note that studies with local control as a primary endpoint 2,3,15 have generally reported higher rates of local failure than those with other primary endpoints, such as disease-free survival. 16,17 This most likely reflects the diligence in which local failure is assessed and recorded. In addition, some studies only score local failures if they occur in the absence of a distant failure. For example, in the Lung Cancer Study Group, crude rates of local failure for stage IA disease were 6% after lobectomy and 17% after sublobar resections. Local failure was defined as disease recurrence in the ipsilateral lung and mediastinum. However, local failure was only scored if it occurred in the absence of a concomitant distant failure. In the current study, 72 of 140 (51%) local failures occurred with a concomitant distant failure. In those patients who developed concurrent local and distant failures, the true temporal relation between these 2 events is uncertain. Although they were detected concurrently, it remains possible that the local failure occurred before, and was a cause of, the distant failure Cancer vember 15, 2009
6 Local Recurrence of Early Stage Lung Cancer/Kelsey et al Table 2. Univariate and Multivariate Analyses for Local Recurrence in All Patients (n¼975) Factors* Hazards Ratio Univariate Analysis 95% CI Wald Chi-Square P Hazards Ratio Multivariate Analysis 95% CI Wald Chi-Square P Age Gender Female Male Surgical procedure Lobectomy Wedge/segmentectomy Surgical approach Open VATS Hilar lymph node sampling Yes Mediastinal lymph node sampling Yes Size, cm Histology nsquamous < <.0001 Squamous or large cell Histologic differentiation Well Moderate or poorly Lymphovascular space invasion /NS Yes Visceral pleural invasion /NS Yes Pathologic stage IA IB-IIB Surgical margins Negative Positive Adjuvant chemotherapy Yes Adjuvant radiotherapy Yes % CI indicates 95% confidence interval; VATS, video-assisted thoracoscopic surgery; NS, not stated. * The first factor level listed is the reference set. Cancer vember 15,
7 Original Article Table 3. Subgroup (n¼445) Undergoing Lobectomy for Stage IB-II Disease: Univariate and Multivariate Analyses for Local Recurrence Univariate Analysis Multivariate Analysis Factors* Hazards Ratio 95% CI Wald Chi-Square P Hazards Ratio 95% CI Wald Chi-Square P Age Gender Female Male Surgical approach Open VATS Hilar lymph node sampling Yes Mediastinal lymph node sampling Yes Size, cm Histology nsquamous Squamous or large cell Histologic differentiation Well Moderate or poorly Lymphovascular space invasion /NS Yes Visceral pleural invasion /NS Yes Adjuvant chemotherapy Yes Adjuvant radiotherapy Yes % CI indicates 95% confidence interval; VATS, video-assisted thoracoscopic surgery; NS, not stated. * The first factor level listed is the reference set. Finally, local failure rates are often reported as crude percentages, rather than actuarial probabilities. There are statistical limitations with Kaplan-Meier statistics when assessing nonsurvival endpoints, such as time to local failure, due to competing risks. 25 There is no ideal method to correct for competing risks. We did not censor patients for local failure after a distant disease recurrence was identified, but rather assessed all patients until the date of last follow-up or death for patterns of failure. However, only 6 of 140 local recurrences developed >30 days after a distant recurrence was identified. The majority of patients who failed at distant sites initiated systemic chemotherapy, which could potentially have prevented residual local disease from becoming clinically apparent. Although the majority of patients had chest imaging after developing distant metastases, some patients did not. These, and other issues, will cause actuarial local failure rates to be underestimated. In our study of 975 patients with stage I to II NSCLC, the 5-year rate of local failure was 23%. By 5224 Cancer vember 15, 2009
8 Local Recurrence of Early Stage Lung Cancer/Kelsey et al FIGURE 3. Kaplan-Meier curve of time to local failure by multivariate risk factors (squamous/large cell histology and lymphovascular space invasion) in the subgroup of patients undergoing at least a lobectomy for stage IB to II nonsmall cell lung cancer is shown. comparison, the 5-year rate of distant failure was 34%. After excluding those patients who underwent less than optimal surgery (sublobar resections and/or positive surgical margins), and excluding patients with stage IA disease (in whom adjuvant therapy is not typically recommended), the risk of local disease recurrence was 27% at 5 years. This appears sufficiently high to warrant further examination into adjuvant local therapy. Furthermore, certain pathologic features may place patients at particularly high risk of local disease recurrence, such as lymphovascular space invasion and/or squamous or large cell histology. Lymphovascular space invasion predisposes to regional (and distant) spread and may be a marker of occult lymph node involvement. Squamous cell carcinomas often arise from a background of premalignant changes induced by tobacco smoke, often referred to as a field defect. This may predispose to local disease recurrence. Such changes are not routinely and methodically described in pathology reports, making it difficult to evaluate this possibility. Our findings that lymphovascular space invasion and squamous/large cell histology are independent predictors of local disease recurrence will need to be validated in independent datasets. Several surgical and pathologic factors have been associated with a higher risk of local recurrence, the most consistent being limited surgery (wedge or segmentectomy), 14,19,20,26,27 positive surgical margins, and lack of or limited mediastinal sampling. 18,20 In the current study, sublobar resections were associated with a higher risk of local disease recurrence in multivariate analysis but lack of mediastinal sampling was not. Patients with positive surgical margins were more likely to receive RT than patients with negative margins, but the limited number of events made it difficult to evaluate the effectiveness of RT in the presence of positive surgical margins. An accurate assessment of patterns of failure after surgery is helpful to guide postoperative therapy. Given the recognized risk of local recurrence, even in patients with early stage disease, a reanalysis of postoperative RT appears prudent. There is significant concern in proceeding with such a study, and rightly so, given the results of the PORT Meta-analysis Trialists Group indicating a survival detriment in patients with early stage NSCLC. 4 Nevertheless, there are several reasons to support a reassessment of postoperative RT. First, the current analysis suggests that local failure occurs relatively often after lobectomy for early stage disease and appears to be higher than is widely appreciated. Second, just as chemotherapy approaches have improved over the past 20 years (alkylating agents replaced by cisplatin-based regimens), so have RT techniques. Advances in 3-dimensional (3D) treatment planning and radiation delivery systems appear to have improved the therapeutic ratio of RT. Two small randomized trials in which modern 3D treatment planning was used both demonstrated improved local control and trends toward improved survival with postoperative RT in patients with lung cancer. 2,31 Furthermore, prior studies of postoperative RT used generous RT fields, which were directed at the entire mediastinum and often the supraclavicular fossa. This was logical because these studies were largely conducted in the pre-ct era, and there was much uncertainty regarding lobe-specific lymphatic spread 32,33 and patterns of failure after surgery. 34 A better understanding of these issues provides an opportunity to more carefully design RT fields that target the intrathoracic sites at highest risk, and by so doing, enhance the therapeutic ratio. A recent randomized trial of postoperative RT in patients with stage I NSCLC using very small customized RT fields 2 demonstrated a significant improvement in local control without excess toxicity using this approach. Third, the ability of local measures to enhance survival is limited by the risk of distant failure. Local disease recurrence may not influence survival if the risk of distant recurrence is high. The increased use of adjuvant Cancer vember 15,
9 Original Article chemotherapy, with the associated reduction in systemic risk, may allow improvements in local control to be more readily translated into improvements in overall survival. In the recently published ANITA trial, postoperative RT appeared to improve survival for patients with stage III, but not stage II, NSCLC after resection and adjuvant chemotherapy. 35 However, because RT was not a randomized variable, it is not possible to accurately evaluate the effect on either group. Chemotherapy also has the potential to decrease the risk of local failure. The ANITA trial, which to our knowledge is the only recent randomized trial to report patterns of failure, did demonstrate a reduction in the risk of local failure with cisplatin-based chemotherapy. 7 Finally, most patients with early stage NSCLC will not develop local disease recurrence. Identifying those that will, with a high degree of certainty, is not currently possible. Recent studies have shown that gene expression profiles can distinguish patients at particularly high risk of disease recurrence who are more likely to benefit from adjuvant treatment. 36,37 To the best of our knowledge, these genomic signatures have not distinguished between local and distant disease recurrence. If patients at high risk of local recurrence could be reliably identified, this would further improve the therapeutic ratio and may facilitate clinical trials examining the role of postoperative RT in early stage NSCLC. As with any retrospective analysis, the current study has limitations. Although nearly 50% of local recurrences were confirmed with biopsy, the remaining were scored using imaging studies that can overestimate, as well as underestimate, the extent of disease. Furthermore, clinical judgment was necessary when evaluating patterns of failure, in particular distinguishing recurrent disease from second primary lung cancers. Every case was reviewed by 2 physicians to ascertain, to the best of our ability, an accurate description of patterns of failure. We acknowledge that there may have been errors in this process. Furthermore, although pathologists with an expertise in lung cancer rendered an initial interpretation of the pathologic findings in the majority of cases, we did not re-review the pathologic specimens. The primary strength of this analysis is the number of patients analyzed. Indeed, to the best of our knowledge, the current study represents 1 of the largest patterns of failure analyses of patients undergoing surgery for early stage NSCLC. Conclusions Greater than 50% of disease recurrences occurring after surgery for early stage NSCLC involve local sites. The risk of local disease recurrence after surgery for patients with stage I to II NSCLC in the current series was 23%. Despite optimal surgery, current candidates for adjuvant chemotherapy are at relatively high risk of local recurrence. Pathologic factors, in particular squamous or large cell histology and lymphovascular space invasion, may help distinguish those patients at highest risk. Conflict of Interest Disclosures The authors made no disclosures. References 1. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000;47: Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62: Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys. 1980;6: PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from 9 randomised controlled trials. Lancet. 1998;352: n-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311: Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350: Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7: Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352: Collett D. Modeling Survival Data in Medical Research. 2nd ed. London: Chapman & Hall; Cancer vember 15, 2009
10 Local Recurrence of Early Stage Lung Cancer/Kelsey et al 10. Therneau TM, Grambsch PM. Modeling Survival Data. New York: Springer; Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin. 2008;58: Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26: Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60: ; discussion Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC, Brichet AH. Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg. 1996;62: Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol. 1984;2: Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350: Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80: ; discussion Harpole DH Jr, Herndon JE Jr, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76: Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109: Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg. 1981;32: Sawyer TE, Bonner JA, Gould PM, et al. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg. 1999;68: Luzzi L, Voltolini L, Campione A, et al. Pneumonectomy vs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J Cardiovasc Surg (Torino). 2003;44: Kim YT, Kang CH, Sung SW, Kim JH. Local control of disease related to lymph node involvement in non-small cell lung cancer after sleeve lobectomy compared with pneumonectomy. Ann Thorac Surg 2005;79: ; discussion Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J Clin Oncol. 1990;8: Warren WH, Faber LP. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. Five-year survival and patterns of intrathoracic recurrence. J Thorac Cardiovasc Surg 1994;107: ; discussion Lee JH, Machtay M, Kaiser LR, et al. n-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology. 1999;213: Hsu HC, Wang CJ, Huang EY, Sun LM. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. Br J Radiol. 2004;77: Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997;64: ; discussion Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer. 1997;80: Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997;112: Hata E, Hayakawa K, Miyamoto H, et al. Rationale for extended lymphadenectomy for lung cancer. Theor Surg. 1990;5: hl-oser HC. An investigation of the anatomy of the lymphatic drainage of the lungs as shown by the lymphatic spread of bronchial carcinoma. Ann R Coll Surg Engl. 1972;51: [no authors listed]. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Rad Oncol Biol Phys. 2006;65: Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72: Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355: Chen HY, Yu SL, Chen CH, et al. A 5-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356: Cancer vember 15,
Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationFactors Associated With the Development of Brain Metastases
Factors Associated With the Development of Brain Metastases Analysis of 975 Patients With Early Stage Nonsmall Cell Lung Cancer Jessica L. Hubbs, MS 1 ; Jessamy A. Boyd, MD 2 ; Donna Hollis, MS 3 ; Junzo
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationVariability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival
Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPrognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer
Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationPoor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification
CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationRadiotherapy for Locoregional Recurrent Non-Small Cell Lung Cancer
J Lung Cancer 2011;10(1):37-43 Radiotherapy for Locoregional Recurrent Non-Small Cell Lung Cancer Purpose: To retrospectively evaluate the outcomes and complications of curative radiotherapy for locoregionally
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationPrognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule
Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationProton therapy for post-operative radiation therapy of non-small cell lung cancer
Mini-Review Proton therapy for post-operative radiation therapy of non-small cell lung cancer Annemarie Fernandes Shepherd Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ, USA Correspondence
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationDespite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,
More informationHistory of Limited Resection for Non-small Cell Lung Cancer
Review History of Limited Resection for n-small Cell Lung Cancer Haruhiko Nakamura, MD, PhD, 1 Sugishita Kazuyuki, MD, 1 rihito Kawasaki, MD, 1 Masahiko Taguchi, MD, PhD, 1 and Harubumi Kato, MD, PhD 2
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationThoracoscopic Lobectomy: Technical Aspects in Years of Progress
Thoracoscopic Lobectomy: Technical Aspects in 2015 16 Years of Progress 8 th Masters of Minimally Invasive Thoracic Surgery Orlando September 25, 2015 Thomas A. D Amico MD Gary Hock Professor of Surgery
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationLung cancer is a prevalent health problem worldwide. It is the leading cause
Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationN.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationSagar Damle, MD University of Colorado Denver May 23, 2011
Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu
More informationThe Risk of Death From Heart Disease in Patients With Nonsmall Cell Lung Cancer Who Receive Postoperative Radiotherapy
911 The Risk of Death From Heart Disease in Patients With Nonsmall Cell Lung Cancer Who Receive Postoperative Radiotherapy Analysis of the Surveillance, Epidemiology, and End Results Database Brian E.
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationTreatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Treatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Walter J.
More informationResectable left lower lobe non small cell lung cancer with lymph node metastasis is related to unfavorable outcomes
DOI 10.1186/s40880-015-0069-8 Chinese Journal of Cancer ORIGINAL ARTICLE Resectable left lower lobe non small cell lung cancer with lymph node metastasis is related to unfavorable outcomes Wen Feng Ye
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationSegmentectomy versus lobectomy in patients with stage I pulmonary carcinoma
Segmentectomy versus lobectomy in patients with stage pulmonary carcinoma Five-year survival and patterns of intrathoracic recurrence One hundred seventy-three patients with stage (Tl NO, T2 NO) non-small-cell
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More information